Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …

Direct oral anticoagulants (DOACs) have increasingly replaced warfarin for treating patients
with non‐valvular atrial fibrillation (NVAF). DOACs have been demonstrated to be more …

The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …

Background Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban have been
studied as alternatives to warfarin in the prevention of events in patients with nonvalvular …

Background Much direct evidence has proved that the novel oral anticoagulants (NOACs)
are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …